Published within
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
| Type |
Product title / description
|
Pub
|
Price |
CommentWire
|
Roche has agreed to acquire Piramed for $160m plus a milestone payment of $15m, due upon the start of Phase II clinical trials for the company's oncology program. Piramed's oncology and immunology and inflammation programs will add to Roche's already strong portfolio in these therapy areas and the move is in line with Roche's strategy of pursuing these two fastest growing therapeutic segments.
Published By Datamonitor
|
15 Apr 2008 |
|
CommentWire
|
Eli Lilly has completed its purchase of US biotechnology company SGX Pharmaceuticals for $64m. The acquisition is expected to compliment Lilly's pursuit of innovative R&D programs, and represents a further investment by a leading pharmaceutical player in the promising US biotechnology industry.
Published By Datamonitor
|
21 Aug 2008 |
|
Expert View
|
Raptiva's safety profile continues to face US and EU regulatory agency scrutiny, which Datamonitor believes will have significant ramifications for the drug's use in psoriasis and any future employment in transplantation. With fresh concern over the safety of Genentech's drug, alternative therapies are likely to impact upon Raptiva's commercial potential.
Published By Datamonitor
|
23 Feb 2009 |
|
CommentWire
|
Already a widely used therapy in HER-2-positive breast cancer patients, Herceptin now has the potential to establish itself in the equivalent gastric cancer subset following positive survival results in a pivotal trial. However, with other top-selling targeted therapy drugs also in late-stage development for the same indication, competition is on the horizon.
Published By Datamonitor
|
18 Mar 2009 |
|
CommentWire
|
New positive top-line results from a second Phase III clinical trial of sodium oxybate in fibromyalgia show that the drug is on track for FDA approval. As such, the treatment is set to enter the market as the fourth drug to be approved for fibromyalgia in the US. Despite impressive efficacy data, however, prescriptions are likely to be limited by accessibility, price and convenience.
Published By Datamonitor
|
26 Jun 2009 |
|
CommentWire
|
Biogen's MS pipeline has been in the spotlight this week due to negative Phase II data for CDP323 and the company's announcement of an agreement to develop and commercialize Fampridine SR outside the US. While the CDP323 results have led to the drug being shelved, Biogen's continuing activity in broadening its strong MS pipeline shows its resolve in maintaining its leading position in this market.
Published By Datamonitor
|
02 Jul 2009 |
|
CommentWire
|
Despite being one of the two hallmarks for Alzheimer's disease for over a century, little drug development has focused on tau as a therapeutic target. At this year's International Conference for Alzheimer's Disease, two groups presented data suggesting the viability of tau as a target for vaccine development, offering an alternative target for companies keen to boost their neurology pipelines.
Published By Datamonitor
|
22 Jul 2009 |
|
Expert View
|
In recent years, the annual International Conference on Alzheimer's Disease has become the foremost event on the Alzheimer's disease calendar. As a primary hallmark of the disease, beta-amyloid production and deposition have become the focus for drug development. At this year's meeting progress was reported on several beta-amyloid targeted clinical stage pipeline drugs.
Published By Datamonitor
|
22 Jul 2009 |
|
CommentWire
|
Amgen has announced that it has formed a partnership with GlaxoSmithKline to commercialize denosumab for the treatment of postmenopausal osteoporosis in Europe and emerging markets. While this partnership increases denosumab's potential in the EU, the challenge will be to convince payers that the new monoclonal antibody provides a clear clinical advantage over cheap and effective alternatives.
Published By Datamonitor
|
29 Jul 2009 |
|
CommentWire
|
Amgen's Vectibix has failed to meet a secondary endpoint of overall survival in patients with KRAS wild-type metastatic colorectal cancer. This is a setback as initial positive results for the drug had suggested a strong positioning against Erbitux in the first-line. However, Vectibix did show a trend towards an improvement in survival, and Amgen may now consider further trials on this basis.
Published By Datamonitor
|
06 Nov 2009 |
|
|«
«
|
1
|
2
|
3
|
4
|
5
|
»
»|
No help is available.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Business Insight reports are an objective source of data, analysis and market insight
Insight for technology vendors into customer trends and pain points from key business decision makers.
Butler Group's thought leadership, opinion, with end user case studies and product profiles for key vendors.
Butler Group's vendor ranking and assessment model groups vendors into Outperform, Perform, and Under-perform categories.
Butler Group's thought leadership, opinion, and best practice with technology audits, product comparisons and rankings.
Opinion and market commentary from Datamonitor's industry experts.
Company profiles deliver detailed insight into how companies are organized and function with SWOT analysis.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Company reports provide detailed company evaluations.
Opinion and market commentary from Datamonitor's industry experts.
Opinion and market commentary from Datamonitor's industry experts.
Track industry events, markets, products, customers, prospects, competitors and partners
Country profiles presenting easy-to-digest summaries and standardized data.
Databooks use charts and tables to provide a data-centric view of a particular market or category
Opinion and market commentary from Datamonitor's industry experts.
Comprehensive category data, including market value, volume, segmentation and share, with analysis.
Industry profiles provide standardized market data (including size & segmentation) and competitive analysis.
Market sizing and forecast data for a market or sector delivered in spreadsheet format.
Track industry events, markets, products, customers, prospects, competitors and partners
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Ovum's research addresses the commercial impact of technology and market changes in telecoms, software and IT services.
Reports and briefs contain analyst driven analysis and opinion covering a specific market or issue.
Opinion and market commentary from Datamonitor's industry experts.
Insight for technology vendors into customer trends and pain points from key business decision makers.
Business information covering a specific market or issue.